SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
175.59
-3.40 (-1.90%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close178.99
Open176.42
Bid164.10 x 800
Ask176.25 x 900
Day's Range175.00 - 176.82
52 Week Range123.73 - 182.47
Volume1,416,679
Avg. Volume976,932
Market Cap52.085B
Beta (3Y Monthly)0.82
PE Ratio (TTM)11.15
EPS (TTM)15.74
Earnings DateN/A
Forward Dividend & Yield1.06 (0.59%)
Ex-Dividend Date2018-09-06
1y Target Est199.30
Trade prices are not sourced from all markets
  • Financial Timesyesterday

    [$$] Takeda dissident investors make last push to block Shire deal

    A dissident group of shareholders is making a final push to block Takeda’s £46bn acquisition of Shire by bringing in the most influential member of the Japanese pharmaceutical group’s founding family to support its campaign. Kunio Takeda, the group’s former chairman and the last member of the Takeda family to run the 237-year-old drugmaker, opposes the takeover of the Irish rare diseases specialist, according to two people close to Mr Takeda.

  • GlobeNewswireyesterday

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswireyesterday

    Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting

    – 16 November 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on rare diseases, today announced additional data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™, evaluating the efficacy and safety of subcutaneously administered lanadelumab in HAE, will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2018 Annual Scientific Meeting. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of oedema (swelling) in various parts of the body. Data showed that patients treated with lanadelumab 300 mg every two weeks experienced significantly fewer HAE attacks, were less likely to have moderate or severe attacks or use rescue medication (primary and secondary endpoints), and were more likely to be HAE attack-free than those treated with placebo.

  • Moody'syesterday

    Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade

    Moody's Japan K.K. has assigned A2 ratings to Takeda Pharmaceutical Company Limited's (A2 review for downgrade) proposed senior unsecured notes. These new notes are under review for downgrade as are Takeda's ...

  • David Abrams Buys Shire, Boosts Lithia Motors
    GuruFocus.com3 days ago

    David Abrams Buys Shire, Boosts Lithia Motors

    David Abrams (Trades, Portfolio), founder of Abrams Capital Management, increased his holdings of the following stocks during the third quarter. Warning! GuruFocus has detected 7 Warning Signs with SHPG. The guru established new position in Shire PLC ADR (SHPG), buying 2,247,133 shares.

  • David Abrams Buys 3 Stocks in 3rd Quarter
    GuruFocus.com3 days ago

    David Abrams Buys 3 Stocks in 3rd Quarter

    David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, released his third-quarter portfolio last week, listing three new holdings. Warning! GuruFocus has detected 7 Warning Signs with SHPG.

  • Shire's Filing Accepted by FDA for Gattex's Label Expansion
    Zacks3 days ago

    Shire's Filing Accepted by FDA for Gattex's Label Expansion

    The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

  • GlobeNewswire3 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GuruFocus.com4 days ago

    Daniel Loeb Purchases 7 Stocks in 3rd Quarter

    Third Point's buying slows as it seeks 'compounders of value'

  • GlobeNewswire4 days ago

    U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel Syndrome

    Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel.

  • Reuters5 days ago

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million (£749.3 million) in fees from Takeda Pharmaceutical's $62 billion (48.3 billion pounds) takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.

  • Reuters5 days ago

    Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.

  • Reuters5 days ago

    Takeda sets vote date, aims to close $62 billion Shire deal on January 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion (47.92 billion pounds) acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.

  • Financial Times5 days ago

    [$$] Takeda sets date for shareholder vote on £46bn Shire deal

    The key vote comes as a group of shareholders, including several founding family members of Takeda, steps up a campaign to derail a deal that Japan’s largest drugmaker sees as critical to catapulting itself into the ranks of the world’s biggest pharmaceutical companies. “With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,” Christophe Weber, the chief executive of Takeda, said in a statement. Takeda, which initially said it would hold the vote in early 2019, has brought the date forward as management has become increasingly confident about the prospects of the company securing a two-thirds approval from shareholders to issue new shares to finance the acquisition.

  • GlobeNewswire5 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire5 days ago

    Publication of Scheme Document

    Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the “Scheme Document”). Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com. A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.

  • Financial Times5 days ago

    [$$] Takeda and Shire to pay almost $1bn in deal fees and expenses

    Drugmakers Takeda and Shire  are set to pay almost $1bn in expenses and fees to advisers, an enormous payday for the banks and law firms working on Japan’s largest overseas corporate takeover. Bankers ...

  • Reuters8 days ago

    Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

    Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday. Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio. Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.

  • Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
    Zacks8 days ago

    Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

    Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

  • GlobeNewswire8 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Moody's8 days ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade

    Moody's Japan K.K. has assigned A2 ratings to Takeda Pharmaceutical Company Limited's (A2 review for downgrade) proposed senior unsecured notes. These new notes are under review for downgrade as are Takeda's ...

  • Takeda Hires Banks for Euro Bonds to Finance Shire Takeover
    Bloomberg9 days ago

    Takeda Hires Banks for Euro Bonds to Finance Shire Takeover

    (Bloomberg) -- Takeda Pharmaceutical Co. Ltd has picked banks to arrange a euro bond offering to finance its $62 billion acquisition of larger rival Shire Plc.

  • The Wall Street Journal10 days ago

    [$$] Shire Spinout Mirum Pharmaceuticals Launches With $120 Million

    Some drug companies are parting with compounds they can’t afford to develop or that are no longer a priority. Several startups have gathered these assets, which have often been tested in clinical trials. Mirum secured a drug that is set for Phase III studies.

  • GlobeNewswire10 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of SHP.L earnings conference call or presentation 1-Nov-18 2:00pm GMT

    Q3 2018 Shire PLC Earnings Call